Olaratumab for the treatment of soft tissue sarcoma.
Deshpande HA, Cecchini M, Ni Choileain S, Jones R. Olaratumab for the treatment of soft tissue sarcoma. Drugs Of Today 2017, 53: 247-255. PMID: 28492292, DOI: 10.1358/dot.2017.53.4.2560077.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasPhase II studyTissue sarcomasII studyMetastatic diseaseOverall survivalOngoing phase III studiesRandomized phase II studyPlatelet-derived growth factor receptor alphaProgression-free survivalPhase III studyStandard chemotherapy regimensGrowth factor receptor alphaUnited States FoodMechanism of actionChemotherapy regimensIII studyOngoing trialsSolid malignanciesReceptor alphaPhase IbDrug AdministrationSignificant improvementFDA approvalOlaratumab
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply